Overview
US vascular device maker's Q1 sales rose 11%, slightly beating analyst expectations
Q1 EPS grew 42% year-over-year, driven by higher pricing and geographic expansion
Outlook
Company sees Q2 sales of $70.5 mln to $72.5 mln, midpoint $71.5 mln, up 11%
LeMaitre Vascular expects full-year 2026 sales of $277 mln to $283 mln, midpoint $280 mln, up 12%
Company forecasts full-year 2026 EPS of $2.93 to $3.08, midpoint $3.00, up 19%
Result Drivers
PRODUCT SALES - Artegraft, grafts, valvulotomes, and carotid shunts posted record sales, with Artegraft up 36% worldwide, aided by international launch
GEOGRAPHIC EXPANSION - EMEA and APAC regions posted strong sales growth, with all three geographies reaching record sales
GROSS MARGIN GAINS - Higher pricing and manufacturing efficiencies contributed to a 350 bps increase in gross margin
Company press release: ID:nGNX4DmlLg
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Slight Beat*
$66.55 mln
$66.53 mln (10 Analysts)
Q1 EPS
$0.68
Q1 Net Income
$15.68 mln
Q1 Gross Profit
$48.4 mln
Q1 Income From Operations
$17.78 mln
Q1 Pretax Profit
$19.67 mln
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for LeMaitre Vascular Inc is $113.00, about 0.9% above its May 5 closing price of $112.00
The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 33 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)